Market Overview - US stock market showed mixed results with Dow Jones up by 0.91%, while Nasdaq fell by 0.82% and S&P 500 decreased by 0.11% [1] - Notable declines in major tech stocks: Tesla down 5.34%, Nvidia down 2.97%, Meta Platforms down 2.56%, Microsoft down 1.08%, and Google A down 0.22% [1] - Amazon and Apple saw gains, with Amazon up 0.49% and Apple up 1.29% [1] Solar Industry - Solar concept stocks generally rose as the US Senate removed Trump's proposals regarding wind and solar projects from the tax law draft [2] - The Senate also overwhelmingly rejected Trump's AI regulatory ban with a vote of 99 to 1 [2] Economic Indicators - The US ISM Manufacturing Index has contracted for four consecutive months [4] - The JOLTS job openings for May were significantly better than expected [4] Domestic Developments - China's Central Economic Committee emphasized the need to advance the construction of a unified national market and promote high-quality development of the marine economy [6] - The Shanghai government announced a subsidy program for electric bicycles, providing a one-time subsidy of 500 yuan for consumers trading in old bikes for new ones [13] Electric Vehicle Market - BYD reported sales of 382,600 new energy vehicles in June, while Xiaomi delivered 25,000 units and XPeng saw a year-on-year increase of 224% in deliveries [8] Semiconductor and Technology - New and existing companies are making significant advancements in semiconductor technology, with companies like Huawai Design and TaiLing Micro achieving notable stock price increases [19] - Google signed a power purchase agreement with Commonwealth Fusion Systems, marking a significant step in the emerging nuclear fusion energy sector [14] IPO and Market Activity - He Yuan Bio's IPO application was approved on the same day it was submitted, marking a significant event for the STAR Market [8] - Several companies are expected to see significant profit increases in the upcoming half-year, including Xinhe Cheng with a projected net profit of 3.3 to 3.75 billion yuan, representing a 50% to 70% year-on-year growth [17]

Summary of Key Points Core Viewpoint - The convertible bonds issued by Shenzhen Chipscreen Biosciences Co., Ltd. have seen minimal conversion activity, with a significant majority remaining unconverted as of June 30, 2025. Group 1: Convertible Bond Issuance Overview - The company issued convertible bonds amounting to RMB 500 million on July 5, 2022, with a maturity period of six years until July 4, 2028 [2] - The bonds began trading on the Shanghai Stock Exchange on July 28, 2022, under the name "微芯转债" and code "118012" [2] - The initial conversion price was set at RMB 25.36 per share, adjusted to RMB 25.26 per share on June 4, 2024, due to share repurchase and cancellation [2] Group 2: Conversion Status - From April 1, 2025, to June 30, 2025, no bonds were converted into shares, resulting in a conversion amount of RMB 0 and a total of 0 shares converted, which is 0% of the total shares before conversion [1][2] - As of June 30, 2025, a cumulative total of RMB 124,000 has been converted into 4,875 shares, representing 0.0012% of the total shares before conversion [1][2] - The total amount of unconverted convertible bonds as of June 30, 2025, stands at RMB 499,876,000, accounting for 99.9752% of the total issuance [3] Group 3: Share Capital Changes - The total share capital remained unchanged at 407,796,477 shares, with no new shares issued from the convertible bonds [4]

Group 1: Company Announcements - Changchun High-tech plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and international brand image [1] - Saisir reported June sales of 46,086 new energy vehicles, a year-on-year increase of 4.44%, with a total of 172,100 units sold in the first half of the year, down 14.35% year-on-year [1] - Hangzhou High-tech announced a change in controlling shareholder to Jirong Weiye, with stock resuming trading on July 2, 2025 [1] Group 2: Financial Performance - Guomai Technology expects a net profit of 125 million to 156 million yuan for the first half of 2025, a year-on-year increase of 60.52% to 100.33% [2] - Kid King anticipates a net profit of 120 million to 160 million yuan for the first half of 2025, representing a year-on-year growth of 50% to 100% [2] - Mould Technology received a project from a well-known North American electric vehicle company, with expected total sales of 1.236 billion yuan over five years [3] Group 3: Regulatory and Compliance - *ST Yuancheng is under investigation by the China Securities Regulatory Commission for suspected false disclosures in financial reports [4] - The company received a notice of investigation on July 1, 2025, which may lead to significant penalties and potential delisting [4] Group 4: Market Activity - Changcheng Military Industry's stock has experienced significant volatility, with a cumulative price deviation exceeding 20% over three trading days, indicating potential irrational speculation [5] - Anglikang has only one innovative drug project, ALK-N001, currently in Phase I clinical trials, highlighting the long and uncertain nature of drug development [6] Group 5: Sales and Contracts - Beiqi Blue Valley's subsidiary reported a 139.73% year-on-year increase in sales for the first half of the year [7] - Dong'an Power's engine sales in June increased by 82.79% year-on-year [7] - Pudong Construction's subsidiary won multiple major projects with a total bid amount of 1.964 billion yuan [7]

证券代码：688321 证券简称：微芯生物 公告编号：2025-040 深圳微芯生物科技股份有限公司 一、药品基本情况 1、产品名称：CS231295 片 受理号：IND176942 受理日期：2025 年 6 月 30 日 适应症：晚期实体瘤 申请事项：新药临床试验申请 自愿披露关于CS231295临床试验申请获得FDA受理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 深圳微芯生物科技股份有限公司（以下简称"公司"）的全资子公司微芯生 物科技（美国）有限公司于 6 月 30 日收到美国食品药品监督管理局（以下简称 "FDA"）的书面回复，公司自主研发的 CS231295 关于晚期实体瘤的临床试验申 请获得 FDA 受理。 本次申请为新药临床试验申请，自提交日起若 30 日内未收到 FDA 的通知， 或 30 日内收到 FDA 同意开展临床试验的通知，公司即可按照提交的方案开展临 床试验。临床试验能否最终开展存在不确定性，敬请广大投资者注意防范投资风 险，谨慎决策。现将相关情况公告如下： 三、风险 ...

| 证券代码：688321 | 证券简称：微芯生物 | 公告编号： 2025-039 | | --- | --- | --- | | 转债代码：118012 | 转债简称：微芯转债 | | 深圳微芯生物科技股份有限公司 关于可转债转股结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●本季度转股情况：深圳微芯生物科技股份有限公司（以下简 称"公司"）向不特定对象发行可转换公司债券"微芯转债"自 2023 年 1 月 11 日起可转换为公司股份，自 2025 年 4 月 1 日至 2025 年 6 月 30 日期间，"微芯转债"共有人民币 0 元转换为公司股票， 转股数量为 0 股，占"微芯转债"转股前公司已发行股份总额的 0%。 ●累计转股情况：截至 2025 年 6 月 30 日，"微芯转债"累计有 人民币 124,000 元已转换为公司股票，转股数量为 4,875 股，占 "微芯转债"转股前公司已发行股份总额的 0.0012%； ●未转股可转债情况：截至 2025 年 6 月 30 ...

Core Viewpoint - Micron Biomedical (688321.SH) announced that its wholly-owned subsidiary, Micron Biomedical Technology (USA) Co., Ltd., received a written response from the FDA, indicating that the clinical trial application for its self-developed drug CS231295 for advanced solid tumors has been accepted by the FDA [1] Group 1 - The drug CS231295 is a selective Aurora B inhibitor that may provide new solutions for various types of tumors and brain metastases with similar genetic defects [1] - Currently, there are no similar designed drugs entering the clinical trial phase globally [1] - The application is for a new drug clinical trial, and if the FDA does not respond within 30 days of submission or provides consent to proceed within that timeframe, the company can commence clinical trials as per the submitted plan [1]

Core Viewpoint - The A-share innovative drug sector experienced a significant surge on July 1, driven by favorable policy announcements from the National Medical Insurance Administration and the National Health Commission, which aim to support the high-quality development of innovative drugs [1][4]. Group 1: Market Performance - Frontier Biotech reached a 20% limit-up, with other companies like Guizhou BaiLing, Saily Medical, and AngliKang also hitting their limits [2]. - Notable stock performances included: - Frontier Biotech: 12.05 (+20.02%) - Kexing Pharmaceutical: 44.19 (+15.62%) - Yuyuan Pharmaceutical: 22.00 (+15.55%) - Shuyitai: 43.00 (+15.34%) - Rongchang Biotech: 68.39 (+13.04%) [3]. Group 2: Policy Support - The new measures encourage the use of medical insurance data for innovative drug research and development, enhancing collaboration among medical, insurance, and pharmaceutical sectors [4][6]. - The policy promotes the expansion of commercial health insurance investments in innovative drugs, establishing a new directory for innovative drugs that exceed basic insurance coverage [6]. - The National Medical Insurance Administration plans to streamline the application process for including drugs in both commercial and medical insurance directories, reducing the administrative burden on companies [6]. Group 3: Industry Outlook - The innovative drug sector is in a golden development phase, with over 20 first-class innovative drugs approved for market entry from January to May, marking a five-year high [7]. - Chinese pharmaceutical companies are accelerating their international expansion, with over 90 overseas licensing transactions expected in 2024, totaling over $50 billion [7]. - Significant licensing deals include: - 12.5 billion USD deal by 3SBio - 53.3 billion USD collaboration between CSPC and AstraZeneca - 42.3 billion USD agreement by Rongchang Biotech [7]. - Several biotech firms are increasing R&D investments through share placements, with funds directed towards global R&D pipelines [8]. Group 4: Investment Sentiment - Analysts agree on the sustainable growth potential of the innovative drug sector, emphasizing the "innovation + internationalization" trend as a core focus for the pharmaceutical industry [9]. - Investment opportunities are seen in the upstream pharmaceutical supply chain, advanced manufacturing, and healthcare services, with a focus on companies with strong growth potential and profitability [9].

Group 1 - The stock price of Microchip Biotech (688321) increased by 12.19% to 23.75 yuan as of June 27, 2025, with a market cap of 9.685 billion yuan [1] - The company reached a peak price of 25.6 yuan on June 24, 2025, and a low of 21.09 yuan on June 23, 2025 [1] - Microchip Biotech was listed among the top five securities on the Dragon and Tiger List due to a price increase of 15% on June 23, 2025, marking its first appearance in the last five trading days [2][5] Group 2 - The company's 2024 financial report indicates a net loss of 115 million yuan, with total assets of 3.251 billion yuan, total liabilities of 1.334 billion yuan, and operating revenue of 658 million yuan [3] - The company has strong innovative drug research capabilities, with core products receiving new treatment guideline recommendations and new indications approved [3] - Despite the strengths, the company faces challenges such as a single product line, increasing debt pressure, and competition in the market, along with a decline in the price of its core product, Xidabonan [3][4] Group 3 - The company's credit rating is A+ with a stable outlook, as assessed by Zhongjian Pengyuan, indicating that core products have competitive advantages [3][4] - The company’s convertible bonds also received an A+ credit rating with a stable outlook [4] - The company is expected to see new growth momentum from the approval of new indications included in medical insurance [3]

证券代码：688321 证券简称：微芯生物 转债代码：118012 债券简称：微芯转债 深圳微芯生物科技股份有限公司 向不特定对象发行可转换公司债券 受托管理事务报告 （2024 年度） 债券受托管理人 （深圳市福田区福田街道福华一路 119 号安信金融大厦） 二零二五年六月 重要声明 本报告依据《可转换公司债券管理办法》（以下简称"《管理办法》"）、《深 圳微芯生物科技股份有限公司（作为发行人）与国投证券股份有限公司（作为受 托管理人）关于深圳微芯生物科技股份有限公司向不特定对象发行可转换公司债 券之受托管理协议》（以下简称"《受托管理协议》"）、《深圳微芯生物科技股 份有限公司向不特定对象发行可转换公司债券募集说明书》（以下简称"《募集 说明书》"）、《深圳微芯生物科技股份有限公司 2024 年年度报告》等相关公开 信息披露文件、第三方中介机构出具的专业意见等，由本次债券受托管理人国投 证券股份有限公司（以下简称"国投证券"）编制。国投证券对本报告中所包含的 从上述文件中引述内容和信息未进行独立验证，也不就该等引述内容和信息的真 实性、准确性和完整性做出任何保证或承担任何责任。 本报告不构成对投资者进行或 ...

证券代码：688321 证券简称：微芯生物 公告编号：2025-038 转债代码：118012 转债简称：微芯转债 深圳微芯生物科技股份有限公司 关于"微芯转债"2025 年付息的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和 完整性依法承担法律责任。 重要内容提示： 深圳微芯生物科技股份有限公司（以下简称"公司"）于 2022 年 7 月 5 日发行的可转换公司债券将于 2025 年 7 月 7 日开始支付 自 2024 年 7 月 5 日至 2025 年 7 月 4 日期间的利息。根据《深圳微 芯生物科技股份有限公司向不特定对象发行可转换公司债券募集 说明书》（以下简称"《募集说明书》"）有关条款的规定，现将有 关事项公告如下： 一、可转债发行上市概况 经中国证券监督管理委员会"证监许可[2022]1234 号"文同意 1 可转债付息债权登记日：2025 年 7 月 4 日 可转债除息日：2025 年 7 月 7 日 可转债兑息日：2025 年 7 月 7 日 注册，公司于 2022 年 7 月 5 日向不特定对象发行可转换公司债券 5 ...